Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance

Eli I. Lev, Rajnikant T. Patel, Kelly J. Maresh, Sasidhar Guthikonda, Juan Granada, Timothy DeLao, Paul F. Bray, Neal Kleiman

Research output: Contribution to journalArticlepeer-review

455 Scopus citations


OBJECTIVES: We sought to evaluate the response to clopidogrel among aspirin-resistant versus aspirin-sensitive patients undergoing percutaneous coronary intervention (PCI). BACKGROUND: Wide variability has been reported in response to aspirin and clopidogrel. There are limited data on the simultaneous responses to both drugs. METHODS: Elective PCI patients (n = 150) who received aspirin for <1 week but not clopidogrel were included. All patients received bivalirudin during PCI. Blood samples were drawn at baseline and 20 to 24 h after a 300-mg clopidogrel dose. Aspirin resistance was defined by ≥2 of 3 criteria: rapid platelet function analyzer-ASA score ≥550, 5 μmol/l adenosine diphosphate (ADP)-induced aggregation ≥70%, and 0.5 mg/ml arachidonic acid-induced aggregation ≥20%. Clopidogrel resistance was defined as baseline minus post-treatment aggregation ≤10% in response to 5 and 20 μmol/l ADP. RESULTS: Nineteen (12.7%) patients were resistant to aspirin and 36 (24%) to clopidogrel. Nine (47.4%) of the aspirin-resistant patients were also clopidogrel resistant. Aspirin-resistant patients were more likely to be women and have diabetes than were aspirin-sensitive patients. They also had lower response to clopidogrel, assessed by platelet aggregation and activation markers (flow cytometry-determined PAC-1 binding and P-selectin expression). Elevation of creatine kinase-myocardial band after stenting occurred more frequently in aspirin-resistant versus aspirin-sensitive patients (38.9% vs. 18.3%; p = 0.04) and in clopidogrel-resistant versus clopidogrel-sensitive patients (32.4% vs. 17.3%; p = 0.06). CONCLUSIONS: Aspirin-resistant patients as a group have reduced response to clopidogrel. Furthermore, we have identified a unique group of dual drug-resistant patients who may be at increased risk for thrombotic complications after PCI.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalJournal of the American College of Cardiology
Issue number1
StatePublished - Jan 3 2006

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance'. Together they form a unique fingerprint.

Cite this